EUVIMEDEUVIMED entdecken
Open Access

Fusariosis in Patients With Hematologic Malignancies in the Era of Antifungal Prophylaxis

Paulina Vega iD, Pooja Bhattacharyya, Joshua A Lieberman iD, Thomas M Kuczmarski iD, Leah Hampson Yoke iD, Lisa M So, Hayden Z Smith, Regina Lengermann, Seth Cohen, David N Fredricks, Steven A Pergam iD

Transplant Infectious Disease · 2026

DOI: 10.1111/tid.70203 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Infectious Disease, 2026. Verfasst von Paulina Vega und 10 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Infection Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Fusariosis, Antifungal Agents, Hematologic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIAID NIH HHS, National Cancer Institute Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Invasive fusariosis (IF) is an uncommon but frequently fatal infection among patients with hematologic malignancies (HM). Despite widespread mould‐active prophylaxis, breakthrough infections and treatment failures may occur. We aim to describe the clinical epidemiology, diagnostic approaches, antifungal management strategies, and outcomes of IF in the era of routine antifungal prophylaxis.

Methods

We conducted a retrospective study of all cancer patients diagnosed with IF at a tertiary cancer center that met probable/proven criteria for IF from 2015 to 2024. We collected data on demographics, oncologic history, diagnostics, therapy, and outcomes.

Results

Twenty‐two patients met criteria for proven IF. Most had acute myeloid leukemia (73%), and many underwent prior hematopoietic cell transplant (36%); nearly all were neutropenic (96%, median:48 days). Skin was the most common clinical site of infection (68%), followed by sino‐pulmonary involvement (41%); fungemia occurred in 32%. Fever (77%) and skin nodules (64%) were frequent, while serum galactomannan was uniformly negative. Most common species complex was Fusarium fujikuroi . In our cohort, 82% occurred during antifungal prophylaxis, most often posaconazole. Minimum inhibitory concentrations were high for azoles and lower for amphotericin B and terbinafine. Antifungal regimens ranged from monotherapy to triple therapy. Overall mortality was 68%, of which 45% of deaths were attributed to IF. Mortality did not differ by antifungal regimen, species complexes, or presence of fungemia.

Conclusions

IF remains a life‐threatening infection in patients with HM, often presenting as disseminated disease, despite prophylaxis. High azole MICs and the observed diversity of antifungal regimens highlight the ongoing uncertainty regarding optimal treatment and the need for prospective studies to define the role of combination therapy. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FusariosisAntifungal AgentsHematologic NeoplasmsHumansRetrospective StudiesFemaleMaleMiddle AgedFusariumBreakthrough InfectionsAdultAgedMicrobial Sensitivity TestsNeutropeniaHematopoietic Stem Cell TransplantationTriazoles

Stichwörter der Autor:innen

Fusariumantifungalsfusariosishematologicimmunocompromisedmalignanciesneutropeniatransplant

Substanzen

Antifungal AgentsposaconazoleTriazoles

Autor:innen und Institutionen

  • Vaccine and Infection Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Department of Medicine, University of Washington, Seattle, Washington, USA.
  • Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA.
  • MaineHealth Maine Medical Center, Portland, Maine, USA.
  • Department of Medicine, University of Texas Southwestern, Dallas, Texas, USA.

ORCID-Profile: Paulina Vega, Joshua A Lieberman, Thomas M Kuczmarski, Leah Hampson Yoke, Steven A Pergam

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • National Cancer Institute Cancer Center
  • National Institute of Allergy and Infectious Diseases of the National Institutes of Health

Zitieren

APA

Vega, P., Bhattacharyya, P., Lieberman, J. A., Kuczmarski, T. M., Yoke, L. H., So, L. M., Smith, H. Z., Lengermann, R., Cohen, S., Fredricks, D. N., & Pergam, S. A. (2026). Fusariosis in Patients With Hematologic Malignancies in the Era of Antifungal Prophylaxis. Transplant Infectious Disease. https://doi.org/10.1111/tid.70203

Vancouver

Vega P, Bhattacharyya P, Lieberman JA, Kuczmarski TM, Yoke LH, So LM, et al. Fusariosis in Patients With Hematologic Malignancies in the Era of Antifungal Prophylaxis. Transplant Infectious Disease. 2026. doi:10.1111/tid.70203

BibTeX
@article{Vega2026,
  author = {Vega, Paulina and Bhattacharyya, Pooja and Lieberman, Joshua A and Kuczmarski, Thomas M and Yoke, Leah Hampson and So, Lisa M and Smith, Hayden Z and Lengermann, Regina and Cohen, Seth and Fredricks, David N and Pergam, Steven A},
  title = {Fusariosis in Patients With Hematologic Malignancies in the Era of Antifungal Prophylaxis},
  journal = {Transplant Infectious Disease},
  year = {2026},
  doi = {10.1111/tid.70203}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche